Global AI in Drug Discovery Market

AI in Drug Discovery Comprehensive Study by Application (Immuno-oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, Others), Technology (Machine Learning, Deep Learning, Others), End-User (Pharmaceutical & Biotechnology, Research Organizations, Academic & Government Institutes), Component (Software, Services) Players and Region - Global Market Outlook to 2028

AI in Drug Discovery Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 39.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About AI in Drug Discovery
Artificial intelligence for drug discovery is a technology that uses and different algorithms that value add in decision-making processes for drug discovery. The increasing cases of rare diseases and demand for personalized drugs are the major factor fueling the growth of the global Al for Drug Discovery marker.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
CAGR39.5%


Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global AI in Drug Discovery market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

IBM Corporation (United States), Microsoft (United States), Google (United States), NVIDIA Corporation (United States), Atomwise, Inc. (United States), Deep Genomics (Canada), Cloud Pharmaceuticals (United States), Insilico Medicine (United States), Benevolent AI (United Kingdom) and Exscientia (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Cyclica (Canada), BIOAGE (United States), Numerate (United States), Numedii (United States), Envisagenics (United States), twoXAR (United States), OWKIN, Inc. (United States), XtalPi (United States), Verge Genomics (United States) and Berg LLC (United States).

Segmentation Overview
AMA Research has segmented the market of Global AI in Drug Discovery market by , Application (Immuno-oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases and Others) and Region.



On the basis of geography, the market of AI in Drug Discovery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology, the sub-segment i.e. Machine Learning will boost the AI in Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Pharmaceutical & Biotechnology will boost the AI in Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Component, the sub-segment i.e. Software will boost the AI in Drug Discovery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Research Applying AI to Drug Discovery is Accelerating and Data Sharing

Market Growth Drivers:
Increasing Pressure on the Drug Manufacturer to Reduce Drug Price and Growing Number of Cross-Industry Collaborations and Partnerships

Challenges:
Protecting Intellectual Property and Data

Restraints:
Limited Awareness, High Cost and Technical Limitation of AI Decision-Making

Opportunities:
Implementation of AI reduces researches and development gap in the drug manufacturing process and help in the targeted manufacturing of the drugs. and Huge Investments in Research & Developments




Key Target Audience
Al in Drug Discovery Vendors, Pharmaceutical & Healthcare Organizations, Research Institutes, Governments and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Immuno-oncology
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Others
By Technology
  • Machine Learning
  • Deep Learning
  • Others

By End-User
  • Pharmaceutical & Biotechnology
  • Research Organizations
  • Academic & Government Institutes

By Component
  • Software
  • Services

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Pressure on the Drug Manufacturer to Reduce Drug Price
      • 3.2.2. Growing Number of Cross-Industry Collaborations and Partnerships
    • 3.3. Market Challenges
      • 3.3.1. Protecting Intellectual Property and Data
    • 3.4. Market Trends
      • 3.4.1. Research Applying AI to Drug Discovery is Accelerating
      • 3.4.2. Data Sharing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global AI in Drug Discovery, by Application, Technology, End-User, Component and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global AI in Drug Discovery (Value)
      • 5.2.1. Global AI in Drug Discovery by: Application (Value)
        • 5.2.1.1. Immuno-oncology
        • 5.2.1.2. Neurodegenerative Diseases
        • 5.2.1.3. Cardiovascular Diseases
        • 5.2.1.4. Metabolic Diseases
        • 5.2.1.5. Others
      • 5.2.2. Global AI in Drug Discovery by: Technology (Value)
        • 5.2.2.1. Machine Learning
        • 5.2.2.2. Deep Learning
        • 5.2.2.3. Others
      • 5.2.3. Global AI in Drug Discovery by: End-User (Value)
        • 5.2.3.1. Pharmaceutical & Biotechnology
        • 5.2.3.2. Research Organizations
        • 5.2.3.3. Academic & Government Institutes
      • 5.2.4. Global AI in Drug Discovery by: Component (Value)
        • 5.2.4.1. Software
        • 5.2.4.2. Services
      • 5.2.5. Global AI in Drug Discovery Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. AI in Drug Discovery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. IBM Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Microsoft (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Google (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. NVIDIA Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Atomwise, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Deep Genomics (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cloud Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Insilico Medicine (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Benevolent AI (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Exscientia (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global AI in Drug Discovery Sale, by Application, Technology, End-User, Component and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global AI in Drug Discovery (Value)
      • 7.2.1. Global AI in Drug Discovery by: Application (Value)
        • 7.2.1.1. Immuno-oncology
        • 7.2.1.2. Neurodegenerative Diseases
        • 7.2.1.3. Cardiovascular Diseases
        • 7.2.1.4. Metabolic Diseases
        • 7.2.1.5. Others
      • 7.2.2. Global AI in Drug Discovery by: Technology (Value)
        • 7.2.2.1. Machine Learning
        • 7.2.2.2. Deep Learning
        • 7.2.2.3. Others
      • 7.2.3. Global AI in Drug Discovery by: End-User (Value)
        • 7.2.3.1. Pharmaceutical & Biotechnology
        • 7.2.3.2. Research Organizations
        • 7.2.3.3. Academic & Government Institutes
      • 7.2.4. Global AI in Drug Discovery by: Component (Value)
        • 7.2.4.1. Software
        • 7.2.4.2. Services
      • 7.2.5. Global AI in Drug Discovery Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. AI in Drug Discovery: by Application(USD Million)
  • Table 2. AI in Drug Discovery Immuno-oncology , by Region USD Million (2017-2022)
  • Table 3. AI in Drug Discovery Neurodegenerative Diseases , by Region USD Million (2017-2022)
  • Table 4. AI in Drug Discovery Cardiovascular Diseases , by Region USD Million (2017-2022)
  • Table 5. AI in Drug Discovery Metabolic Diseases , by Region USD Million (2017-2022)
  • Table 6. AI in Drug Discovery Others , by Region USD Million (2017-2022)
  • Table 7. AI in Drug Discovery: by Technology(USD Million)
  • Table 8. AI in Drug Discovery Machine Learning , by Region USD Million (2017-2022)
  • Table 9. AI in Drug Discovery Deep Learning , by Region USD Million (2017-2022)
  • Table 10. AI in Drug Discovery Others , by Region USD Million (2017-2022)
  • Table 11. AI in Drug Discovery: by End-User(USD Million)
  • Table 12. AI in Drug Discovery Pharmaceutical & Biotechnology , by Region USD Million (2017-2022)
  • Table 13. AI in Drug Discovery Research Organizations , by Region USD Million (2017-2022)
  • Table 14. AI in Drug Discovery Academic & Government Institutes , by Region USD Million (2017-2022)
  • Table 15. AI in Drug Discovery: by Component(USD Million)
  • Table 16. AI in Drug Discovery Software , by Region USD Million (2017-2022)
  • Table 17. AI in Drug Discovery Services , by Region USD Million (2017-2022)
  • Table 18. South America AI in Drug Discovery, by Country USD Million (2017-2022)
  • Table 19. South America AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 20. South America AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 21. South America AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 22. South America AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 23. Brazil AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 24. Brazil AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 25. Brazil AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 26. Brazil AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 27. Argentina AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 28. Argentina AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 29. Argentina AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 30. Argentina AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 31. Rest of South America AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 32. Rest of South America AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 33. Rest of South America AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 34. Rest of South America AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 35. Asia Pacific AI in Drug Discovery, by Country USD Million (2017-2022)
  • Table 36. Asia Pacific AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 37. Asia Pacific AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 38. Asia Pacific AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 39. Asia Pacific AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 40. China AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 41. China AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 42. China AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 43. China AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 44. Japan AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 45. Japan AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 46. Japan AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 47. Japan AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 48. India AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 49. India AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 50. India AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 51. India AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 52. South Korea AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 53. South Korea AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 54. South Korea AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 55. South Korea AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 56. Taiwan AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 57. Taiwan AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 58. Taiwan AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 59. Taiwan AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 60. Australia AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 61. Australia AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 62. Australia AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 63. Australia AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 68. Europe AI in Drug Discovery, by Country USD Million (2017-2022)
  • Table 69. Europe AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 70. Europe AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 71. Europe AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 72. Europe AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 73. Germany AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 74. Germany AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 75. Germany AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 76. Germany AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 77. France AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 78. France AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 79. France AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 80. France AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 81. Italy AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 82. Italy AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 83. Italy AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 84. Italy AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 85. United Kingdom AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 86. United Kingdom AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 87. United Kingdom AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 88. United Kingdom AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 89. Netherlands AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 90. Netherlands AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 91. Netherlands AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 92. Netherlands AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 93. Rest of Europe AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 94. Rest of Europe AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 95. Rest of Europe AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 96. Rest of Europe AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 97. MEA AI in Drug Discovery, by Country USD Million (2017-2022)
  • Table 98. MEA AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 99. MEA AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 100. MEA AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 101. MEA AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 102. Middle East AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 103. Middle East AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 104. Middle East AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 105. Middle East AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 106. Africa AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 107. Africa AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 108. Africa AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 109. Africa AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 110. North America AI in Drug Discovery, by Country USD Million (2017-2022)
  • Table 111. North America AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 112. North America AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 113. North America AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 114. North America AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 115. United States AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 116. United States AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 117. United States AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 118. United States AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 119. Canada AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 120. Canada AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 121. Canada AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 122. Canada AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 123. Mexico AI in Drug Discovery, by Application USD Million (2017-2022)
  • Table 124. Mexico AI in Drug Discovery, by Technology USD Million (2017-2022)
  • Table 125. Mexico AI in Drug Discovery, by End-User USD Million (2017-2022)
  • Table 126. Mexico AI in Drug Discovery, by Component USD Million (2017-2022)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. AI in Drug Discovery: by Application(USD Million)
  • Table 138. AI in Drug Discovery Immuno-oncology , by Region USD Million (2023-2028)
  • Table 139. AI in Drug Discovery Neurodegenerative Diseases , by Region USD Million (2023-2028)
  • Table 140. AI in Drug Discovery Cardiovascular Diseases , by Region USD Million (2023-2028)
  • Table 141. AI in Drug Discovery Metabolic Diseases , by Region USD Million (2023-2028)
  • Table 142. AI in Drug Discovery Others , by Region USD Million (2023-2028)
  • Table 143. AI in Drug Discovery: by Technology(USD Million)
  • Table 144. AI in Drug Discovery Machine Learning , by Region USD Million (2023-2028)
  • Table 145. AI in Drug Discovery Deep Learning , by Region USD Million (2023-2028)
  • Table 146. AI in Drug Discovery Others , by Region USD Million (2023-2028)
  • Table 147. AI in Drug Discovery: by End-User(USD Million)
  • Table 148. AI in Drug Discovery Pharmaceutical & Biotechnology , by Region USD Million (2023-2028)
  • Table 149. AI in Drug Discovery Research Organizations , by Region USD Million (2023-2028)
  • Table 150. AI in Drug Discovery Academic & Government Institutes , by Region USD Million (2023-2028)
  • Table 151. AI in Drug Discovery: by Component(USD Million)
  • Table 152. AI in Drug Discovery Software , by Region USD Million (2023-2028)
  • Table 153. AI in Drug Discovery Services , by Region USD Million (2023-2028)
  • Table 154. South America AI in Drug Discovery, by Country USD Million (2023-2028)
  • Table 155. South America AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 156. South America AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 157. South America AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 158. South America AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 159. Brazil AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 160. Brazil AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 161. Brazil AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 162. Brazil AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 163. Argentina AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 164. Argentina AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 165. Argentina AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 166. Argentina AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 167. Rest of South America AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 168. Rest of South America AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 169. Rest of South America AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 170. Rest of South America AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 171. Asia Pacific AI in Drug Discovery, by Country USD Million (2023-2028)
  • Table 172. Asia Pacific AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 173. Asia Pacific AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 174. Asia Pacific AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 175. Asia Pacific AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 176. China AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 177. China AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 178. China AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 179. China AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 180. Japan AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 181. Japan AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 182. Japan AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 183. Japan AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 184. India AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 185. India AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 186. India AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 187. India AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 188. South Korea AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 189. South Korea AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 190. South Korea AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 191. South Korea AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 192. Taiwan AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 193. Taiwan AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 194. Taiwan AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 195. Taiwan AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 196. Australia AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 197. Australia AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 198. Australia AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 199. Australia AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 200. Rest of Asia-Pacific AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 204. Europe AI in Drug Discovery, by Country USD Million (2023-2028)
  • Table 205. Europe AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 206. Europe AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 207. Europe AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 208. Europe AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 209. Germany AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 210. Germany AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 211. Germany AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 212. Germany AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 213. France AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 214. France AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 215. France AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 216. France AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 217. Italy AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 218. Italy AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 219. Italy AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 220. Italy AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 221. United Kingdom AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 222. United Kingdom AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 223. United Kingdom AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 224. United Kingdom AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 225. Netherlands AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 226. Netherlands AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 227. Netherlands AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 228. Netherlands AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 229. Rest of Europe AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 230. Rest of Europe AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 231. Rest of Europe AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 232. Rest of Europe AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 233. MEA AI in Drug Discovery, by Country USD Million (2023-2028)
  • Table 234. MEA AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 235. MEA AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 236. MEA AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 237. MEA AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 238. Middle East AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 239. Middle East AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 240. Middle East AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 241. Middle East AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 242. Africa AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 243. Africa AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 244. Africa AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 245. Africa AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 246. North America AI in Drug Discovery, by Country USD Million (2023-2028)
  • Table 247. North America AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 248. North America AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 249. North America AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 250. North America AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 251. United States AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 252. United States AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 253. United States AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 254. United States AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 255. Canada AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 256. Canada AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 257. Canada AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 258. Canada AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 259. Mexico AI in Drug Discovery, by Application USD Million (2023-2028)
  • Table 260. Mexico AI in Drug Discovery, by Technology USD Million (2023-2028)
  • Table 261. Mexico AI in Drug Discovery, by End-User USD Million (2023-2028)
  • Table 262. Mexico AI in Drug Discovery, by Component USD Million (2023-2028)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global AI in Drug Discovery: by Application USD Million (2017-2022)
  • Figure 5. Global AI in Drug Discovery: by Technology USD Million (2017-2022)
  • Figure 6. Global AI in Drug Discovery: by End-User USD Million (2017-2022)
  • Figure 7. Global AI in Drug Discovery: by Component USD Million (2017-2022)
  • Figure 8. South America AI in Drug Discovery Share (%), by Country
  • Figure 9. Asia Pacific AI in Drug Discovery Share (%), by Country
  • Figure 10. Europe AI in Drug Discovery Share (%), by Country
  • Figure 11. MEA AI in Drug Discovery Share (%), by Country
  • Figure 12. North America AI in Drug Discovery Share (%), by Country
  • Figure 13. Global AI in Drug Discovery share by Players 2022 (%)
  • Figure 14. Global AI in Drug Discovery share by Players (Top 3) 2022(%)
  • Figure 15. Global AI in Drug Discovery share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. IBM Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 18. IBM Corporation (United States) Revenue: by Geography 2022
  • Figure 19. Microsoft (United States) Revenue, Net Income and Gross profit
  • Figure 20. Microsoft (United States) Revenue: by Geography 2022
  • Figure 21. Google (United States) Revenue, Net Income and Gross profit
  • Figure 22. Google (United States) Revenue: by Geography 2022
  • Figure 23. NVIDIA Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. NVIDIA Corporation (United States) Revenue: by Geography 2022
  • Figure 25. Atomwise, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Atomwise, Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Deep Genomics (Canada) Revenue, Net Income and Gross profit
  • Figure 28. Deep Genomics (Canada) Revenue: by Geography 2022
  • Figure 29. Cloud Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cloud Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 31. Insilico Medicine (United States) Revenue, Net Income and Gross profit
  • Figure 32. Insilico Medicine (United States) Revenue: by Geography 2022
  • Figure 33. Benevolent AI (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Benevolent AI (United Kingdom) Revenue: by Geography 2022
  • Figure 35. Exscientia (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. Exscientia (United Kingdom) Revenue: by Geography 2022
  • Figure 37. Global AI in Drug Discovery: by Application USD Million (2023-2028)
  • Figure 38. Global AI in Drug Discovery: by Technology USD Million (2023-2028)
  • Figure 39. Global AI in Drug Discovery: by End-User USD Million (2023-2028)
  • Figure 40. Global AI in Drug Discovery: by Component USD Million (2023-2028)
  • Figure 41. South America AI in Drug Discovery Share (%), by Country
  • Figure 42. Asia Pacific AI in Drug Discovery Share (%), by Country
  • Figure 43. Europe AI in Drug Discovery Share (%), by Country
  • Figure 44. MEA AI in Drug Discovery Share (%), by Country
  • Figure 45. North America AI in Drug Discovery Share (%), by Country
List of companies from research coverage that are profiled in the study
  • IBM Corporation (United States)
  • Microsoft (United States)
  • Google (United States)
  • NVIDIA Corporation (United States)
  • Atomwise, Inc. (United States)
  • Deep Genomics (Canada)
  • Cloud Pharmaceuticals (United States)
  • Insilico Medicine (United States)
  • Benevolent AI (United Kingdom)
  • Exscientia (United Kingdom)
Additional players considered in the study are as follows:
Cyclica (Canada) , BIOAGE (United States) , Numerate (United States) , Numedii (United States) , Envisagenics (United States) , twoXAR (United States) , OWKIN, Inc. (United States) , XtalPi (United States) , Verge Genomics (United States) , Berg LLC (United States)
Select User Access Type

Key Highlights of Report


Sep 2023 213 Pages 79 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global AI in Drug Discovery Market Quantitative research analysis
Global AI in Drug Discovery Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as IBM Corporation (United States), Microsoft (United States), Google (United States), NVIDIA Corporation (United States), Atomwise, Inc. (United States), Deep Genomics (Canada), Cloud Pharmaceuticals (United States), Insilico Medicine (United States), Benevolent AI (United Kingdom) and Exscientia (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Research Applying AI to Drug Discovery is Accelerating " is seen as one of major influencing trends for AI in Drug Discovery Market during projected period 2022-2028.
The AI in Drug Discovery market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global AI in Drug Discovery Market Report?

Have a Query? Click Here

Other Related Reports

Dosimetry Technology Comprehensive Study by Type (Active Dosimeter, Passive Dosimeter), Application (Patient Monitoring, Occupational Radiation Monitoring, Area Radiation Monitoring, Others), Solutio...
$ 3750
Consumer Genomics Comprehensive Study by Application (Genetic Relatedness, Diagnostics, Wellness and Nutrition, Ancestry, Reproductive Health, Others), Technology (Polymerase Chain Reaction (PCR), Se...
$ 3750
Workplace Stress Management Comprehensive Study by Delivery Mode (Personal Fitness Advisors, Meditation Specialists, Individual Counselors, Others), Service (Meditation & Yoga, Stress Assessment, Pro...
$ 3750
Interoperability Solutions In Healthcare Comprehensive Study by Type (Software Solutions, Services), Application (Diagnosis, Treatment, Others), Interoperability Level (Foundational Interoperability,...
$ 4200
Biobanking For Medicine Comprehensive Study by Application (Regenerative Medicine, Life Science Research, Clinical Research), Product and Service (Equipment, Consumables, Services, Software), Sample ...
$ 3750
3-D Mammography Comprehensive Study by Type (Screening, Diagnostics), Application (Diagnostic Purpose, Treatments of Cancer), End-User (Hospitals, Surgical Clinics, & Diagnostic Imaging Centers, Brea...
$ 3750